Abstract
Unraveling the genetic mechanisms of Fuchs endothelial corneal dystrophy has opened new possibilities for future targeted medical therapy of the disease. Until these possibilities mature, regenerative semi-surgical approaches by cell injection or cell sheet transfer could help expand the donor pool, and possibly enable autologous transplantation. Descemet membrane stripping alone and acellular Descemet membrane transfer are more immediate surgical approaches that could be temporary treatments in some patients, though there is a lack of understanding of the factors that predict success for these procedures. Regardless of approach, clinical trials will be necessary, and clinicians should therefore try to standardize their methods of assessing disease severity and the outcomes of intervention.
Original language | English (US) |
---|---|
Pages (from-to) | 709-713 |
Number of pages | 5 |
Journal | Klinische Monatsblatter fur Augenheilkunde |
Volume | 235 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2018 |
Keywords
- Fuchs endothelial corneal dystrophy
- ROCK inhibitor
- TCF4 gene
- cell injection
- endothelial keratoplasty
- trinucleotide repeat expansion
ASJC Scopus subject areas
- Ophthalmology